PI3K/Akt/mTOR · target hub
Phosphatidylinositol 4-phosphate 3-kinase catalytic subunit type 2 alpha (PI3K-C2α)
PIK3C2A encodes the class II PI3K α isoform, converting PI(4)P (among inputs) to PI(3,4)P₂ at diverse membranes with roles in RTK-linked endocytosis/recycling, vesicle trafficking, and cytoskeletal/adhesion crosstalk—parallel to, but distinct from, class I PIP₃–Akt signaling; do not equate pathway readouts with plasma-membrane PIP₃ production.
| Type / example | Domain / context (brief) |
|---|---|
| Expression context | Tissue/cell-type–dependent expression |
| Rare variants | Sporadic variants—require functional validation |
| Pathway coupling | Co-occurs with neighboring nodes on the hub |
Naming and prevalence vary by cohort and assay—annotate clinically with COSMIC, ClinVar, OncoKB, and datasheets; research context only.
Examples below reflect common literature and public resources (e.g., CCLE, DepMap)—validate genotypes, expression, and passage in your own stocks before committing assays.
Human tissues and primary cells require ethics/IRB approval; tumors are heterogeneous—record histotype, site, and preservation conditions.
Overexpression vs endogenous PIK3C2A can differ in dosage, splicing, and compartmentation—in organoids/PDX, record passage, matrix, and drug history.
Adds PIK3C2A keyword bias atop the PI3K/Akt/mTOR antibody pool—if sparse, use presets above or global search.
This content supports research reagents and pathway education—not medical advice. Annotate mutations, drug indications, and protocols with authoritative databases, datasheets, and institutional oversight.
Last reviewed: 2026-05-18
See the PI3K/Akt/mTOR hub for neighboring nodes and assay guidance—cross-check MAPK, RTK, metabolism, and autophagy pages as needed.